Kibow Biotech LLC – Trademark Portfolio
Entity Type: 16
Kibow Biotech LLC holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include KIBOW, RENADYL, KIBOW FORTIS, ENTERIC DIALYSIS, and INTESTINAL DIALYSIS. The owner is based in Newtown Square, PA.
4781 West Chester Pike
Newtown Square, PA 19073
Showing of trademarks Trademarks
Trademark Classifications
Kibow Biotech LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Kibow Biotech LLC have?
Kibow Biotech LLC has 5 U.S. trademarks filed with the USPTO. Of these, 5 registered.
What trademark classes does Kibow Biotech LLC file in?
Kibow Biotech LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Kibow Biotech LLC's most well-known trademarks?
Kibow Biotech LLC's registered trademark portfolio includes well-known marks such as KIBOW, RENADYL, KIBOW FORTIS, ENTERIC DIALYSIS, and INTESTINAL DIALYSIS. These are among 5 currently registered trademarks in the portfolio.
What is Kibow Biotech LLC's trademark registration success rate?
Kibow Biotech LLC has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.